CIMG — what changed in the latest 10-Q
A section-by-section comparison of CIMG's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-11
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +17 | −15 | ~11 | 39 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~5 | 1 |
| Risk factors | Text added/removed | 0 | 0 | ~1 | 0 |
| Other information | Text added/removed | +1 | −1 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
In the fourth quarter of the fiscal year ended September 30, 2024, we launched our health-focused product line in Asia, the Maca Series. Maca, a plant native to South America and a member of the Brassicaceae family, is known for its nutritional value and adaptogenic properties. Often referred to as …
On March 4, 2026, the Company received a written notice from Nasdaq that the Panel had determined to delist the Company’s Common Stock from The Nasdaq Stock Market due to the Company’s failures to comply with Nasdaq Listing Rules 5550(a)(2), 5250(c)(1), 5550(b)(1), and 5620(a). Trading in the Compan…
On May 26, 2026, the Listing Council affirmed the Panel’s decision to suspend and delist the Company’s Common Stock. On June 22, 2026, the Company filed an application with the U.S. Securities and Exchange Commission (the “SEC”) pursuant to Section 19(d)(2) of the Securities Exchange Act of 1934, as…
On July 24, 2026, the SEC issued an order establishing a briefing schedule in the review proceeding. Pursuant to the order, the Company’s brief in support of its application for review is due on August 24, 2026, Nasdaq’s brief in opposition is due on September 23, 2026, and any reply brief is due on…
Results of Operations (comparison of the three months ended June 30, 2026 and 2025)
Text removed vs the prior filing · source: 10-Q · 2026-05-11
In the fourth quarter of the fiscal year ended September 30, 2024, we launched our health-focused product line in Asia, the Maca Series.
Maca, a plant native to South America and a member of the Brassicaceae family, is known for its nutritional value and adaptogenic properties. Often referred to as “South American ginseng,” Maca is prized for its ability to support stamina, vitality, and overall wellness. It is primarily cultivated i…
On March 4, 2026, the Company received a written notice from Nasdaq that the Panel had determined to delist the Company’s Common Stock from The Nasdaq Stock Market due to the Company’s failures to comply with Nasdaq Listing Rules 5550(a)(2), 5250(c)(1), 5550(b)(1), and 5620(a). Trading in the Compan…
Results of Operations (comparison of the three months ended March 31, 2026 and 2025)
For the three months ended March 31, 2026, the Homology of Medicine and Food Series, Computing Power Product Series, and Maca Product Series generated revenues of $428,786, $2,649,785, and $136,420 respectively, accounting for 13.34%, 82.42%, and 4.24% of the total revenue. Our total revenue was $3,…
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-13
On August 11, 2026, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Nasdaq Board of Directors had declined to call for review of the May 26, 2026 decision of the Nasdaq Listing and Hearing Review Council (the “Listing Council”). Accordingly, p…
Text removed vs the prior filing · source: 10-Q · 2026-05-11
On March 5, 2026, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to increase the number of authorized shares of the Company’s Common Stock. The amendment increased the Company’s authorized shares of Common Stock from 600,000,000 share…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice